The treatment—apart from controlling bronchial and nasal manifestations, bacterial superinfections, and obesity—includes systemic or preferably local steroid administration, biological treatment with (omalizumab), anti-IL-5 antibody (mepolizumab), an antibody targeting the IL-5 receptor (benralizumab), and a recombinant human antibody binding to the IL-4 receptor (dupilumab). Here, IL5 is linked to Obesity.